Fab is the most efficient format to express functional antibodies by yeast surface display by Sivelle, Coline et al.
HAL Id: cea-02100007
https://hal-cea.archives-ouvertes.fr/cea-02100007
Submitted on 15 Apr 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Fab is the most efficient format to express functional
antibodies by yeast surface display
Coline Sivelle, Raphaël Sierocki, Kelly Ferreira-Pinto, Stéphanie Simon,
Bernard Maillère, Hervé Nozach
To cite this version:
Coline Sivelle, Raphaël Sierocki, Kelly Ferreira-Pinto, Stéphanie Simon, Bernard Maillère, et al.. Fab
is the most efficient format to express functional antibodies by yeast surface display. mAbs, Taylor &
Francis, 2018, 10 (5), pp.720-729. ￿10.1080/19420862.2018.1468952￿. ￿cea-02100007￿
1 
 
Fab is the most efficient format to express functional antibodies by 1 
yeast surface display 2 
Coline Sivelle1*, Raphaël Sierocki1*, Kelly Ferreira-Pinto1, Stéphanie Simon2, Bernard 3 
Maillere1, Hervé Nozach1 4 
 5 
1 Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA, Université Paris-Saclay, F-6 
91191 Gif/Yvette, France. 7 
2 Service de Pharmacologie et Immunoanalyse (SPI), CEA, INRA, Laboratoire d’Etudes et de 8 
Recherches en Immunoanalyse, Université Paris-Saclay, F-91191 Gif/Yvette, France. 9 
* These authors contributed equally to this work 10 
 11 
Abstract 12 
Multiple formats are available for engineering of monoclonal antibodies (mAbs) by yeast surface 13 
display, but they do not all lead to efficient expression of functional molecules. We therefore expressed 14 
four anti-tumor necrosis factor and two anti-IpaD mAbs as single-chain variable fragment (scFv), 15 
antigen-binding fragment (Fab) or single-chain Fabs and compared their expression levels and antigen-16 
binding efficiency. Although the scFv and scFab formats are widely used in the literature, 2 of 6 17 
antibodies were either not or weakly expressed. In contrast, all 6 antibodies expressed as Fab revealed 18 
strong binding and high affinity, comparable to that of the soluble form. We also demonstrated that 19 
the variations in expression did not affect Fab functionality and were due to variations in light chain 20 
display and not to misfolded dimers. Our results suggest that Fab is the most versatile format for the 21 
engineering of mAbs. 22 
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Introduction 33 
Over the past 20 years, yeast surface display (YSD) has emerged as a very potent tool for 34 
protein engineering. It is a very proficient platform for de novo identification of new binders in naïve1 35 
or immune libraries.2, 3 YSD is also used for the engineering of many antibodies, principally to identify 36 
mutants with improved affinity4, 5 selectivity, stability and expression.4-7 Affinity-matured antibodies 37 
have been developed against multiple antigens such as tumor necrosis factor (TNF),8 fluorescein,9 38 
botulinum neurotoxin type A,10 carcinoembryonic antigen,11 epidermal growth factor receptor12 and 39 
streptavidin.13 Engineering of other properties of antibodies such as pH sensitivity or antigen specificity 40 
has also been described.14, 15 41 
Engineering of pre-existing antibodies using YSD relies on the anchoring of antibody fragments 42 
on the surface of yeast cells via fusion with a cell wall protein. Various formats are described in the 43 
literature for the functional display of antibody fragments on yeast cells, such as single-chain variable 44 
fragment (scFv), antigen-binding fragment (Fab) or single-chain Fab (scFab), although they are known 45 
to lead to variable levels of antibody expression.2, 4, 10, 16 Yeast display of IgG has also been reported 46 
with secretion and capture strategies,17, 18 but, to our knowledge, not as a conventional fusion with a 47 
yeast surface anchor protein. In most cases, antibody fragments are presented using the Aga2p-based 48 
display system, which permits either N-terminal or C-terminal fusion,4 but the lack of comparative 49 
studies does not facilitate the choice of the appropriate formats to be used. 50 
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ScFv molecules are the smallest functional entity (30 kDa) that includes the complete antigen-51 
binding site of an antibody. This entity comprises the two variables domains VH and VL connected by 52 
a flexible linker that prevents their dissociation.  53 
Fab are composed of the light chain (VL + CL) and a heavy chain (VH + CH1) connected by an 54 
interchain disulfide bond. Several studies have reported the expression of Fab molecules on the 55 
surface of yeast cells using either a bigenic plasmid13 or two distinct plasmids10, 14, 19 to allow separate 56 
expression of the two chains. Expression levels of Fab molecules are generally considered as lower 57 
than those of scFv molecules in E. coli,20, 21 at the surface of phages22, 23 and also on the surface of yeast 58 
cells.10  59 
The scFab derived from Fab is obtained through introduction of a polypeptide linker 60 
connecting the light chain and the heavy chain. Thus, it combines some advantages of the scFv (single 61 
chain and one expression plasmid, level of expression) with the stability and lower tendency to 62 
aggregate of the Fab.2, 23 The linker prevents the display of unpaired heavy chain antibodies (devoid of 63 
light chain), which can sometimes interfere with the selection steps.2 ScFab molecules carry a flexible 64 
linker of variable length (32 to 80 amino acids) and an optional inter-chain disulfide bond.2, 24 Deletion 65 
of carboxy terminal cysteine residues (ΔC) of the CL and CH1 domains results in a scFabΔC format, 66 
which has increased expression levels in E. coli. 23  67 
The scFv is the most popular format for antibody engineering,4 probably because of its very 68 
high level of expression, its small size and the presence of a single peptide chain, which is an advantage 69 
for cloning or sequencing procedures. However, Fab and scFab formats have undeniable advantages, 70 
especially when it comes to stability or for reformatting to IgG molecules after engineering.22 To date, 71 
there is no clear literature consensus regarding the choice of an antibody fragment format suitable for 72 
engineering using yeast cell display. Also, no general study has yet explored the influence of antibody 73 
fragment formats on a diversity of antibodies in this particular context.  74 
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Here, we report the comparison of 4 antibody fragment formats – scFv, scFab with and without 75 
interchain disulfide bond and Fab - for the functional display of 6 antibodies. This study includes a first 76 
set of well-known antibodies - adalimumab, infliximab, golimumab and certolizumab - already used in 77 
clinical settings. This set of antibodies encompasses humanized, chimeric and fully human antibodies, 78 
which share TNF as a common antigen.25 The second set is composed of two chimeric antibodies 79 
targeting the protein IpaD from the needle tip of type III secretion system of Shigella spp obtained 80 
from mouse immunization. The objective of this study was to identify the most suitable format for the 81 
functional expression of antibody fragments on the surface of yeast cells.  82 
 83 
 84 
Results 85 
Conception of yeast surface display vectors allowing expression of scFv, scFab and Fab 86 
antibody fragments 87 
To determine the influence of formats on the expression and functionality of antibody fragments, a 88 
new subset of yeast display plasmids was designed. Four plasmids were constructed for respective 89 
expression of scFv, scFab formats and Fab at the surface of S. cerevisiae cells. Those plasmids share a 90 
common backbone from previously described pCT-L7.5.1,26 including inducible promoter Gal 1-10 and 91 
Aga2p signal peptide [Fig. 1]. Antibody fragments were displayed with a free N-terminus and tethered 92 
to the yeast cell wall by C-terminal fusion with Aga2p,27 in order to avoid possible steric hindrance of 93 
the fusion.  94 
The plasmid pNT scFv encodes a typical scFv composed of VH/VL domains connected by a flexible linker 95 
(G4S)3. We also compared two previously described scFab formats, scFabΔC2 and sc60Fab,24 by 96 
constructing the plasmids pNT scFabΔC and pNT sc60Fab. ScFabs are composed of a VL-CK light chain 97 
connected to the VH-CH1 heavy chain by a flexible linker. The difference between the two formats 98 
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resides in the nature and length of the linker (34 amino acids for scFabΔC versus 60 amino acids for 99 
sc60Fab) and the presence of an inter-chain disulfide bond in sc60Fab connecting the two C-terminal 100 
cysteine residues of CK and CH1. Display of Fab molecules on yeast without any linker was achieved 101 
using the bigenic plasmid pNT Fab where Gal 1-10 promoter and terminator are duplicated to obtain 102 
separate expression of the two chains.  103 
Each plasmid includes a hemagglutinin (HA) tag to report expression of the complete antibody 104 
fragment. For single chain formats (scFv and scFabs), the HA tag is located between the antibody 105 
fragment and the Aga2p subunit. Full Fab expression can be controlled for pNT Fab through the 106 
expression of the light chain with the HA tag or by direct labeling with anti-CK antibody. Expression of 107 
heavy chain can be revealed by the HIS tag located between the heavy chain and Aga2p.  108 
The 6 selected antibodies are IgG1 molecules with CK light chains. The sequences of TNF-specific 109 
antibodies were obtained from the IMGT database.28 The mAbs IpaD_301 and IpaD_318 were obtained 110 
by mouse immunization [data not shown] and engineered to generate chimeric antibodies. These two 111 
antibodies derive from the same parental genes IGHV1-14*01/ IGKV1-117*01 from Mus musculus and 112 
differ by only 7 and 8 mutations in the heavy chain and the light chain, respectively. Together, 24 113 
plasmids corresponding to the sequences of 6 selected antibodies expressed in the 4 antibody formats 114 
were successfully cloned and transformed into yeast. An exhaustive analysis of the 24 constructs was 115 
performed in parallel to investigate the influence of the antibody fragment format on antigen binding.  116 
  117 
Fab format grants functional expression of the largest number of antibodies   118 
To assess the expression and functionality of the constructs, yeast cells were incubated with the 119 
appropriate biotinylated antigen at a concentration far above the expected KD to reach quantitative 120 
binding of the antibody fragments to their antigen. When evaluated by fluorescence-activated cell 121 
sorting (FACS), cells expressing scFvs of adalimumab, certolizumab, golimumab and IpaD_318 122 
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exhibited a high level of fluorescence, indicating quantitative binding of the antigen [Fig 2]. Weaker 123 
fluorescence levels were observed for IpaD_301 scFv, whereas no signal was observed for infliximab 124 
scFv, indicating antigen binding was weak or absent. Functionality of constructs displaying low or 125 
moderate antigen binding was not improved by increased induction times [Supp Data Fig 3]. Antigen 126 
binding was specific, as demonstrated by the lack of cross-reactivity with the non-relevant antigen: 127 
anti-TNF antibodies showed no detectable IpaD binding and anti-IpaD antibodies showed no 128 
detectable TNF binding [Supp Data Fig 1].  129 
Yeast cells expressing scFab corresponding to adalimumab, golimumab and IpaD_318 displayed 130 
quantitative binding to their antigen, both as scFabΔC and sc60Fab formats. Infliximab and IpaD_301 131 
in scFab formats were not or weakly functional, respectively, as attested by the absence of 132 
fluorescence for the corresponding cells. Interestingly, certolizumab scFabΔC showed significant 133 
binding to TNF, while certolizumab sc60Fab with the 60-amino-acid linker and inter-chain disulfide 134 
bond failed to bind TNF. All single-chain constructs were expressed at the surface of cells, as attested 135 
by labeling with anti-HA antibodies, with the notable exception of certolizumab sc60Fab [Supp Data 136 
Fig 2]. Except for this specific construct, the absence of binding of the antibody fragments to their 137 
antigen could not be explained by lack of expression, but rather by a functional deficiency.  138 
In contrast, all of the 6 tested antibodies bound to their antigen when expressed as Fab at the surface 139 
of yeast cells. For each antibody, cells expressing functional Fabs form homogeneous populations with 140 
a clear shift in fluorescence levels compared to non-expressing cells. The proportion of cells expressing 141 
functional Fabs is relatively high (from 46% to 74%). 142 
In our set-up, Fab is the only viable format for functional expression of infliximab and IpaD_301 143 
antibody fragments. Besides, for 5 of 6 antibodies tested, the fluorescence of cells expressing 144 
functional Fab was higher than the fluorescence of the equivalent cells expressing either scFvs or 145 
scFabs. This suggested that Fab molecules were not only active, but also well expressed. For these 146 
reasons, we focused on display of Fab molecules in the rest of the study. 147 
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 148 
Variations of expression in Fab format among antibodies do not affect functionality  149 
We observed that maximal fluorescence levels of Fab-expressing cells vary among antibodies targeting 150 
a common antigen. More specifically, the mean fluorescence intensity of cells displaying functional 151 
infliximab Fabs was much lower than for adalimumab or golimumab, a phenomenon also observed for 152 
IpaD_301 when compared to IpaD_318.  153 
As variations of signal corresponding to antigen binding could be attributed either to differences of 154 
expression levels or to functional differences, dissociation constants (KD) were determined for each 155 
displayed Fab [Fig. 3]. The measured KD values for IpaD_301 and IpaD_318 are 3.2 nM and 1.7 nM, 156 
respectively. This result is in accordance with the KD evaluated by OctetRed with measured affinities 157 
of 1.1 nM and 0.9 nM (Supplementary figure 4). Yeast expressing anti-TNF Fabs show subnanomolar 158 
KD, 161 pM for adalimumab, 102 pM for infliximab, 39 pM for golimumab and 11 pM for certolizumab. 159 
These KD values are consistent with the reported KD determined for the corresponding IgG molecules 160 
using SPR,25 indicating that Fabs expressed on the surface of yeast cells have a very strong affinity for 161 
their antigen.  162 
Interestingly, higher affinity was not correlated with higher level of binding fluorescence. While having 163 
a very good affinity for TNF, infliximab Fab displayed much weaker TNF binding signal compared to 164 
adalimumab Fab, suggesting differences in their expression levels. Thus, additional labeling 165 
experiments were performed to evaluate different expression reporters. In addition to antigen binding 166 
labeling, light chain expression was evaluated with anti-HA or anti-CK antibodies and heavy chain 167 
expression was assessed with anti-HIS antibodies [Fig. 4].  168 
Heavy chain expression showed slight variations between the 6 selected antibodies [Fig. 4a]. Labeling 169 
with anti-HIS antibodies showed homogeneous expression of heavy chains, with IpaD_318 and 170 
adalimumab being somewhat above average. This observation contrasted with light chain expression, 171 
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which showed strong differences across the Fab antibodies [Fig. 4b]. Light chain expression was 172 
significantly higher for IpaD_318 and adalimumab Fabs than for IpaD_301 or infliximab, while 173 
certolizumab and golimumab had intermediate light chain expression levels. Values observed for both 174 
reporters anti-HA or anti-CK were in good agreement, and the relative intensities of constructs were 175 
very similar. Anti-CK antibody yielded a very strong fluorescence signal, thus favoring easy 176 
discrimination of CK-expressing cells.  177 
Antigen binding signals for IpaD_301 and IpaD_318 correlated well with their relative light chain 178 
expression levels [Fig. 4c and Fig. 5]. Very similarly, the TNF binding signal was proportional to the 179 
respective expression levels of adalimumab, infliximab, certolizumab and golimumab light chain of the 180 
Fab [Fig 5]. Direct correlation between light chain expression and antigen binding was confirmed by 181 
simultaneous labeling with anti-CK antibody conjugated to allophycocyanin (APC) and streptavidin R-182 
phycoerythrin (streptavidin-PE) [Fig. 4d].  183 
While having high sequence homology and similar affinities, IpaD_301 and IpaD_318 display significant 184 
differences in expression and antigen binding in all formats tested. For this reason, we investigated a 185 
possible correlation between the biophysical attributes of these two antibodies and their behavior on 186 
the surface of yeast cells. Thus, recombinant expression of complete IgG1 IpaD_301 and IpaD_318 was 187 
performed by transient transfection of HEK293 cells29 followed by protein A purification. Production 188 
yield was slightly higher for IpaD_318 than for IpaD_301 (20 and 14 mg per liter, respectively). Size-189 
exclusion chromatography revealed that both antibodies are predominantly produced as full-length 190 
IgG with low amounts of aggregates for IpaD_318 and even lower amounts for IpaD_301 [Fig. 6]. In 191 
contrast, differential scanning fluorimetry (DSF) analysis reveals that IpaD_301 has a lower melting 192 
temperature (Tm) than IpaD_318, with Tm values of 67.6°C and 69.3°C, respectively [Fig. 6]. 193 
  194 
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Discussion 195 
We carried out a comparative study of expression formats using 6 different antibodies specific for two 196 
different antigens, TNF and IpaD. In our hands, Fab appears to be the most versatile expression format 197 
for display of functional antibodies on the surface of yeast cells. 198 
ScFv is currently the most widespread format for antibody engineering. It has indisputable advantages, 199 
such as its small size, which is particularly convenient for the cloning and sequencing of libraries. Also, 200 
numerous studies have used scFvs successfully to engineer clones with improved properties,4 including 201 
clones derived from adalimumab with improved affinity towards TNF.8 However, some antibodies 202 
display reduced affinity and impaired biophysical properties when expressed as scFv as compared to 203 
the corresponding Fab molecules.23, 30 Indeed, CH1 and CL domains, which are not present in scFv 204 
molecules, participate in the greater stability of Fab and scFab.31, 32 The choice of an adapted format 205 
has also proved to be an important parameter for other approaches such as phage display33, 34 or 206 
recombinant expression of antibody fragments.35  207 
Here, we show that some antibodies do not seem to be active either in the scFv format or in the scFab 208 
format when they are expressed at the surface of yeast cells. In our set-up, two antibodies, infliximab 209 
and IpaD_301, appeared to lack functionality, as suggested by the total absence of antigen binding in 210 
any single-chain format. The presence of CK and CH1 domains, which could have a stabilizing role in 211 
the scFab formats, had no effect on the functionality of the corresponding infliximab and IpaD_301 212 
constructs. We cannot exclude that the presence of a linker between the light chain and the heavy 213 
chain could also cause steric hindrance that impairs functionality.  214 
We found that adalimumab, golimumab and IpaD_318 were well expressed and perfectly able to bind 215 
their antigen as scFv constructs, but also in scFab or Fab formats. Certolizumab was also a very well 216 
expressed and functional antibody in these formats, with the notable exception of the sc60Fab format, 217 
which exhibited very poor expression and had no detectable antigen binding (Supp. Fig 2). These 218 
particular results emphasize that the presence of the two C-terminal cysteine residues in scFab, as well 219 
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as the nature and length of the linker sequence, can dramatically alter expression of scFab molecules 220 
for some antibodies. Moreover, the presence of the interchain disulfide bond can have a major 221 
influence on the stability of the antibody fragment, as recently shown for the adalimumab Fab. 36 The 222 
length of the linker also proved to be an important parameter for the proper packing of light and heavy 223 
chains and possibly the accessibility of the paratope, thus ultimately affecting the function of the scFab 224 
fragment.23, 24  225 
In this study set-up, Fab was the only format that allowed functional display for each of the 6 tested 226 
antibodies. FACS analysis revealed that a very high proportion of induced yeast cells (up to 70%) 227 
expressed Fabs and produced a strong fluorescence signal corresponding to antigen binding. In the 228 
context of protein engineering or affinity maturation, a strong signal would favor an easy 229 
discrimination of high-affinity clones in libraries containing very high numbers of mutants.  230 
Moreover, for anti-TNF molecules, all Fabs expressed on the surface of yeast cells exhibited a high 231 
affinity for their antigen, with KD values close to those reported in the literature, strongly suggesting 232 
that the KD of a protein-protein binding interaction measured on the surface of yeast cells was 233 
essentially equal to that measured using soluble proteins. 37, 38 234 
Deeper analysis of expression reporters in the Fab format indicated a lower display level of light chains 235 
for infliximab and IpaD_301 Fabs. Light chain display correlated perfectly with lower target binding of 236 
these two constructs compared to the other anti-TNF Fabs or IpaD_318 Fab, respectively. Coexpression 237 
of chaperones such as BiP, use of alternative promoters such as Gal10 for the light chain expression, 238 
or introduction of a new secretory leader sequence optimized for antibody secretion such as αMFpp839 239 
might be useful to promote the assembly of light and heavy chains of antibodies during Fab expression. 240 
A recent study demonstrated that co-expression of protein disulfide isomerase (PDI) had a positive 241 
effect on the functionality of some antibodies expressed as Fab on the surface of yeast cells.40 In this 242 
study, Georgiou and co-workers also showed that pairing of antibody chains could be promoted by 243 
fusing the light and heavy chains with dimerization domains such as leucine-zipper proteins. Forced-244 
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dimerization of antibody chains restored functionality for 3 of 13 tested anti-HA antibodies, although 245 
with a lower proportion of cells displaying functional Fab.  246 
Overall, infliximab and IpaD_301 exhibited relatively low expression in every tested format of antibody 247 
fragment. We observed, however, marked differences in the expression profiles of IpaD_301 and 248 
IpaD_318 on the surface of yeast cells in spite of their high sequence homology, with only 7 and 8 249 
mutations in the heavy chain and the light chain, respectively. Production of these two antibodies in a 250 
full-length IgG format reveal that IpaD_301 has lower production titers in HEK cells and also a lower 251 
Tm (67.6°C vs 69.3°C). Interestingly, infliximab is also described as difficult to express in HEK cells41 and 252 
CHO cells,42 with relatively low stability over time.43 A comprehensive study comparing the biophysical 253 
properties of clinical-stage antibodies indicated that infliximab has much lower production titers in 254 
HEK cells than adalimumab, certolizumab and golimumab (6 mg/L for infliximab vs more than 100 255 
mg/mL for the three other anti-TNF antibodies).41 Wittrup and co-workers also reported that infliximab 256 
had a lower Tm (64.5°C vs at least 70°C for the three other anti-TNF antibodies). These observations 257 
are consistent with previously published studies indicating that protein secretion by yeast cells is 258 
correlated with thermodynamic stability.44, 45 Together, this suggests that antibodies with low 259 
thermodynamic stability might have low expression on the surface of yeast cells. 260 
Even as many alternative antibody formats are emerging, most of current therapeutic antibodies on 261 
the market are antibodies in the IgG format.21 Thus, it is essential that the conversion between the 262 
screening format – the antibody fragment – and the IgG antibody does not impair the desired 263 
properties, and in particular affinity for the antigen. From this perspective, use of Fab has strong 264 
advantages. Several reports show that the Fab format tends to retain its binding affinity better than 265 
scFv when converted into IgG.19 Moreover, the presence of a peptide linker in the scFv and scFab 266 
formats or introduction of additional domains such as leucine-zipper dimerization proteins might 267 
introduce bias in the screening of improved clones because of subtle structural changes. Indeed, some 268 
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affinity-enhanced molecules engineered in scFv and scFabΔC formats lost affinity after conversion into 269 
IgG.22 270 
In conclusion, in spite of their practical convenience, single-chain antibody fragment formats such as 271 
scFv and scFab do not always lead to a functional display of antibodies at the surface of yeast cells. In 272 
contrast, we showed that all 6 tested antibodies were functional in the Fab format, with high affinities 273 
for their antigen. Using our Fab expression plasmid, high proportions of yeast cells expressed Fab 274 
molecules and exhibited strong antigen binding signals in FACS, two important properties when getting 275 
started with the affinity maturation process by yeast display in good conditions. These advantages and 276 
the lower risk of losing engineered properties upon conversion into IgG suggest that the Fab format is 277 
the best alternative for the engineering of antibodies using YSD. 278 
 279 
 280 
  281 
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Material and methods 282 
Yeast display vectors construction  283 
Cloning were performed with the SLiCE recombination cloning method46 or classic 284 
restriction/ligature method using E.coli DH5α strain (Invitrogen). For each anti-TNF antibody, 285 
optimized synthetic genes (VH and VL) were ordered from Eurofins Genomics based on the IMGT 286 
sequences. All expression plasmids are derived from previously described pCT-L7.5.126 and share the 287 
CEN/ARS replication origin, TRP auxotrophy marker, colE1 replication origin, Ampicillin resistance gene 288 
and galactose inducible promoter GAL1. Plasmid pCT-L7.5.1 was a gift from Prof. K. Dane Wittrup 289 
(Addgene plasmid # 42900). 290 
Plasmids pNT scFv were modified from parental pCT-L7.5.1 plasmid by modifying the aga2p 291 
signal sequence with a dipeptide spacer27 and a NheI restriction site. A stop codon was inserted at the 292 
3’ end of aga2p gene to obtain plasmids allowing the display of scFv with a free N-terminus end and a 293 
C-terminal anchoring to the yeast cell wall. Synthetic genes corresponding to each scFv were then 294 
cloned using NheI and SpeI restriction sites. 295 
The pNT scFabΔC vector was generated by cloning the coding sequence of the scFabΔC of the 296 
previously described pYDscFab2 between the restriction sites NheI and XhoI of the pNT scFv plasmid. 297 
Plasmid pYDscFab was a gift from Prof. Dennis Burton. Heavy chains and light chains of antibodies were 298 
cloned between NheI/Pfl23II and NcoI/SalI restrictions sites, respectively. 299 
The pNT sc60Fab vectors were generated from pNT scFab plasmids. The linker and the cysteine 300 
residues allowing interchain disulfide bond formation were modified by PCR and homologous 301 
recombination between BssHII and NcoI sites. Heavy chains and light chains of antibodies were cloned 302 
between NheI-Pfl23II and NcoI-SalI restriction sites, respectively.   303 
The bigenic pNT Fab vector was generated by ligation into pNT scFv between SpeI and XhoI of 304 
a synthetic gene (Eurofins Genomics) containing a 6-HIS tag, the Aga2p domain, a Gal1 promoter, an 305 
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aga2p signal sequence, an HA tag and a transcription terminator. The resulting plasmid has two distinct 306 
expression cassettes corresponding to respective expression of light and heavy chains of the Fabs. 307 
Heavy chains and light chains of antibodies were then cloned between NheI/Pfl23II and NcoI/SalI 308 
restrictions sites, respectively. 309 
Yeast transformation 310 
Preparation of competent yeast cells EBY100 (ATCC® MYA-4941™; a GAL1-AGA1 :: URA3 ura3-311 
52 trp1 leu2 Δ1 his3 Δ200 pep4 :: HIS2 prb1Δ1.6R can1 GAL)  was performed according to Suga et al.47 312 
Then, 100 µL of EBY100 electro-competent cells were mixed with 1-2 µg plasmid DNA, transferred to 313 
a pre-chilled electroporation cuvette (Biorad, 165-2086) and pulsed at 2.5 kV, 25 µF (Biorad Gene 314 
Pulser Xcell). Yeast cells were then diluted in 1 mL of sorbitol (1 M), and 200 µL were streaked on SD-315 
CAA agar plates [6.7 g/L yeast nitrogen base without casamino acids, 20 g/L dextrose, 5 g/L casamino 316 
acids, 100 mM sodium phosphate pH 6.0]. 317 
Growth and expression conditions 318 
Yeast cultures were performed in 24 deep-well round-bottom plates. Pre-cultures were 319 
performed by inoculating 3 mL of SD-CAA medium with one colony from selective agar plate and 320 
incubated overnight at 30°C, 200 rpm. The saturated pre-culture (typically OD600 of 8-10) was passaged 321 
in order to obtain an initial culture OD600 of 0.25-0.50. The culture was grown at 30°C until its OD600 322 
reached 0.5-1.0. Cells were centrifuged and re-suspended in 3 mL of SG-CAA galactose induction 323 
medium [6.7 g/L yeast nitrogen base without casamino acids, 20 g/L galactose, 5 g/L casamino acids, 324 
100 mM sodium phosphate, pH 6.0] and induced for 16-36 h at 20°C, 200 rpm. 325 
Yeast labelling and flow cytometry analysis 326 
106 cells were taken from the induced culture and washed with 1 mL PBSF (phosphate-buffered 327 
saline (PBS), bovine serum albumin (BSA) 0.1%) buffer. Cells were resuspended in 50 µL of the target 328 
protein at the desired concentration and incubated at 20°C, 1000 rpm until equilibrium is reached 329 
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(depending on target protein concentration). Cells were washed with 1 mL of ice-cold PBSF to avoid 330 
dissociation and resuspended in ice-cold PBSF containing the appropriate fluorescent reporters: 331 
Streptavidin-PE (Thermo Fisher scientific; catalog number S866; 1:100 dilution), Mouse anti-Human 332 
Kappa Light Chain Antibody APC conjugate (Thermo Fisher scientific; catalog number MH10515; 1:100 333 
dilution), 6x-His Epitope Tag antibody Dylight-650 conjugate (Thermo Scientific, catalog number MA1-334 
21315-D650; 1:100 dilution) or HA Tag Monoclonal Antibody APC conjugate (1:50 dilution). Cells were 335 
incubated on ice in the dark for 15 minutes and analyzed with BD FACS Aria™ III cytometer. 336 
Cell-Binding assays for determining the affinity of antibodies for their antigen 337 
Cell binding assays were performed according to Hunter et al.38 in order to avoid ligand 338 
depletion. 104 to 105 cells were incubated in 50-500 µL of the target protein at the desired 339 
concentrations and incubated at 20°C, 1000 rpm long enough to reach equilibrium. Cells were analyzed 340 
by FACS for their binding fluorescence as described above. Auto-fluorescence was subtracted for each 341 
measure and resulting values were normalized with maximum fluorescence. Data are then fitted with 342 
a non-linear regression analysis to obtain the KD.  343 
Production and purification of IgG IpaD_301 and IpaD_318 344 
IpaD_301 and IpaD_318 antibodies were produced via transient transfection of HEK293 345 
FreestyleTM cells (HEK 293FS). HEK 293FS were transfected as previously described by Subedi et al.48 346 
without the use of Valproic acid using the HEK transient transfection plasmids described by Smith et 347 
al.29 348 
 The day before transfection, cells were sub-cultured in order to be at a density of 2-3.106 349 
cells/mL the next day. The day of the transfection, cells were centrifuged 5 min at 100 g and 350 
resuspended in fresh FreeStyle 293 Expression medium (Thermo-Fisher) to obtain a density of 2.5.106 351 
cells/mL. For a transfection volume of 100 mL, 150 µg of each plasmid (coding for heavy chain and light 352 
chain) was added to the cells at a concentration of 0.5 µg/µL. Cells were incubated 5 min at 37°C, 180 353 
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rpm, 8 % CO2. 1.8 mL of polyethylenimine (PEI) was added at a concentration of 0.5 mg/mL to the cells 354 
(PEI:DNA ratio = 3:1). Cells were subsequently incubated 24h at 37°C, 180 rpm, 8 % CO2.  355 
A day after transfection, 100 mL of fresh EX-CELL® Serum-Free Medium for HEK 293 (Sigma-356 
Aldrich), supplemented with 6 mM L-Glutamine, was added to the transfected culture. Cells were 357 
finally incubated 4 more days at 37°C, 180 rpm, 8 % CO2. Five days after transfection, the supernatant 358 
was harvested by centrifuging the cells at 1000g for 15 min at 4°C and kept on ice until purification. 359 
The supernatant was purified using a HiTrapTM Protein A HP column of 1 mL (GE Healthcare) on an 360 
ÄKTA purifier (GE Healthcare) according to the manufacturer’s description. 361 
Size-exclusion chromatography 362 
A Superdex-200 10/300 GL (GE Healthcare) column was used on an ÄKTA purifier (GE 363 
Healthcare). Runs were monitored with UnicornTM 5.31 software (GE Healthcare).  500 μL of each 364 
sample was applied on the column using a flow rate of 0.7 mL/min and PBS as running buffer.  365 
Fab IpaD_301 and IpaD_318 affinity determination 366 
Fab were prepared from full-length IgG using a Pierce® Fab Micro Preparation Kit. The binding 367 
affinity of Fab IpaD_301 and IpaD_318 was evaluated by biolayer interferometry using an Octet RED96 368 
instrument (Pall ForteBio). Biotinylated IpaD was loaded onto streptavidin biosensors (ForteBio) at a 369 
concentration of 5 µg/mL for 8 min in PBSF (1x PBS, pH 7.4, 0.1% BSA). Fab IpaD_301 and IpaD_318 370 
were then associated with IpaD using 4 different concentrations (20, 10, 5 and 2.5 nM). Duration of 371 
association and dissociation steps were 20 min and 120 min. All steps were performed at 20°C. Data 372 
were collected and analyzed using Octet Software version 10.0.3 (Pall ForteBio). Binding kinetics were 373 
fitted using a 1:1 Langmuir-binding model. 374 
 375 
Thermostability evaluation 376 
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DSF was performed as previously described by Niesen et al.49 using a StepOne Real-Time PCR 377 
System from Applied Biosystems. IgG monomers of IpaD_301 and IpaD_318 purified via SEC were 378 
mixed with the SYPRO Orange reagent. Final dye concentration was 5x and final IgG concentration was 379 
150 µg/mL. The temperature gradient was run from 20 to 90 °C with 1 min equilibration at each degree 380 
centigrade.  381 
 382 
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 388 
Figure 1. Schematic representation of yeast surface display vectors used in this study. 389 
Antibody fragment constructs are tethered to the cell wall of S. cerevisiae cells by C-terminal fusion 390 
with the Aga2p subunit of the a-agglutinin yeast cell surface anchor protein. Expression is controlled 391 
by the tightly regulated galactose-inducible Gal1 promoter. Aga2-ss: native signal sequence of Aga2p 392 
for secretion of the constructs. Single-chain antibody fragments (scFv, scFabΔC and sc60Fab) include 393 
flexible linkers connecting the light chain and the heavy chain. pNT Fab is a bigenic plasmid including 394 
two identical GAL1 promoters for respective expression of light and heavy chains. Cysteine residues 395 
responsible for the formation of the inter-chain disulfide bond connecting CK and CH1 are indicated in 396 
red. Expression of antibody fragments can be monitored using the HA tag for all constructs. A 6His-Tag 397 
sequence can also be used for the monitoring of heavy chain expression when using pNT Fab. 398 
  399 
  400 
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Figure 2. Antigen binding of the 6 selected antibodies expressed as different antibody 401 
fragment formats on the surface of yeast cells. Cells are labeled with biotinylated antigen then with 402 
Streptavidin–PE (Target Binding) before FACS analysis. Selected antigen concentrations are far above 403 
the expected KD to reach a quantitative binding with the antibody fragments. Respective antigen 404 
concentration were 20 nM for anti-TNF antibodies and 50 nM for anti-IpaD antibodies. For each 405 
construct, a FACS histogram shows the fluorescence intensity corresponding to antigen binding (x-axis) 406 
vs the number of detected events (y-axis). Interval gates (bars) are shown to differentiate cells with 407 
detectable antigen binding (mean fluorescence intensity (MFI) score above 103, in green) from cells 408 
with no detectable antigen binding (MFI score under 103, in grey).The 103 cutoff has been obtained by 409 
measuring MFI of cells with a non-relevant antigen, cf. Supplementary figure1. 410 
 411 
Figure 3. Affinity of Fab antibody fragments expressed on the surface of yeast cells. The mean 412 
fluorescence intensity (MFI), determined by FACS analysis, is plotted against varying concentrations of 413 
antigen for every Fab construct, and fit to a monovalent binding model. Measurements were done in 414 
triplicate with independent cultures and inductions. (A) Equilibrium binding constants KD of the four 415 
anti-TNF Fabs for TNF at 20°C. Curve fitting results in a KD of 114 ± 6 nM for adalimumab Fab, 102 ± 14 416 
pM for infliximab Fab, 39 ± 4 pM for golimumab Fab and 11 ± 1 pM for certolizumab Fab. (B) Equilibrium 417 
binding constants KD of the two anti-IpaD Fabs for IpaD at 20°C. KD IpaD_301 Fab = 3.2± 0.3 nM, KD 418 
IpaD_318 Fab = 1.7± 0.2 nM.  419 
  420 
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Figure 4. Antigen binding and expression levels of heavy and light chains of the 6 selected 421 
antibodies expressed as Fab on the surface of yeast cells. Cells were labeled with the appropriate 422 
expression reporter and the mean fluorescence intensity of positive cells was determined by FACS 423 
analysis. For antigen binding, cells were double-labeled with biotinylated antigen and Streptavidin–PE 424 
(target binding) before FACS analysis. (A) Heavy chain expression evaluated with anti-HIS antibody 425 
reporter. (B) Light chain expression evaluated with anti-HA antibody reporter (C) Biotinylated antigen 426 
binding evaluated with Streptavidin-PE (D) Light chain expression evaluated with anti-CK antibody 427 
reporter. Measurements were made in triplicate using cells from independent cultures. 428 
 429 
Figure 5. Representative bivariate flow cytometric analysis of yeast cells expressing Fab 430 
antibody fragments expressed on their surface. Each single dot on the plot designates the APC (y-axis) 431 
and PE (x-axis) fluorescence intensity values for a single yeast cell. Cells were double-labeled with 432 
biotinylated antigen/Streptavidin–PE (target binding) and anti-CK APC labels (Fab expression). Antigen 433 
concentrations in labeling experiments were 20 nM for anti-TNF antibodies and 50 nM for anti-IpaD 434 
antibodies. Functional subpopulations were gated using an inverted gate of the double negative sub-435 
populations. The percentage number correspond to the mean percentage of cells expressing functional 436 
Fabs from three separate inductions. 437 
 438 
Figure 6. Biophysical characterization of IpaD_301 IgG and IpaD_318 IgG expressed by HEK 439 
cells. (A): Size-exclusion chromatograms of the protein A purified IgGs on a Superdex 200 10/300 GL 440 
size-exclusion column for IpaD_301 IgG (black) and IpaD_318 IgG (grey).  Monomeric IgG species elutes 441 
at 15 mL and aggregates or multimeric species elutes between 10 to 12 mL. (B): Tm determination of 442 
IgGs by differential scanning fluorimetry. The fluorescence intensities are normalized to peak values. 443 
Error bars correspond to experiment triplicates. 444 
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Supplementary figure 1. TNFα and IpaD binding of the 6 selected antibodies expressed as Fab on the
surface of yeast cells. Cells are labeled with biotinylated antigen then with Streptavidin–PE (Target
Binding) before FACS analysis. Selected antigen concentrations are far above the expected KD to reach a
quantitative binding with the antibody fragments. Respective antigen concentration were 20 nM for
TNFα and 50 nM for IpaD. For each construct, a FACS histogram shows the fluorescence intensity
corresponding to antigen binding (x-axis) vs the number of detected events (y-axis). Interval gates (bars)
are shown to differentiate cells with detectable antigen binding (in green) from cells with no detectable
antigen binding (in grey).
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Supplementary figure 2. Bivariate flow-cytometric analysis of yeast cells expressing various antibody
fragments on their surface. Each single dot on the plot designate the APC (y-axis) and PE (x-axis) fluorescence
intensity values for a single yeast cell. Cells are double-labeled with biotinylated antigen/Streptavidin–PE
(Target Binding) and anti-HA APC labels (Fab expression). Antigen concentration in labelling experiment were
respectively 20 nM for anti-TNF antibodies and 50 nM for anti-IpaD antibodies. Functional subpopulations in
green were gated using an inverted gate of the double negative subpopulations. The percentage is the
subpopulation of cell expressing Fab.
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Supplementary Figure 3. Antigen binding and expression levels of antibodies IpaD_301 and Infliximab
expressed as Fab antibody fragments on the surface of yeast cells. Cells were labeled with the appropriate
expression reporter and the mean fluorescence intensity of positive cells was determined by FACS analysis. For
antigen binding, cells were double-labeled with biotinylated antigen and Streptavidin–PE (target binding)
before FACS analysis. (A) Light chain expression evaluated with anti-CK antibody reporter (B) Biotinylated
antigen binding evaluated with Streptavidin-PE (C) Percentage of cells with detectable antigen binding.
Measurements were made in triplicate using cells from independent cultures.
A
B
C
KD (M) kon(1/Ms) koff(1/s)
Fab IpaD_301 1.05E-09 2.16E+05 2.25E-04
Fab IpaD_318 9.25E-10 1.59E+05 1.47E-04
Supplementary figure 4. Bio-layer interferometry (Octet Red) KD determination of IpaD_301 Fab and
IpaD_318 Fab. Fab binding to recombinant IpaD was assayed by BLI. Biotinylated IpaD was loaded on
Streptavidin biosensors and equilibrated in PBSF buffer (1X PBS pH 7.4, 0.01% (w/v) BSA) before being
incubated with varying concentrations of each Fab for 20 min. Dissociation was performed in PBSF buffer to
for 2 hours. For each Fab, real time binding profiles using multiple protein concentrations and fitted curves
(1:1 Langmuir binding model) are displayed.
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